13 September 2018
A new report by visiongain predicts that the global vaccine contract manufacturing market will reach $1047.3m in 2019. This forecast and others appear in Vaccine Contract Manufacturing Market Report 2016-2026: Leading Countries, Technologies and Companies, published in December 2015. Visiongain is a business information provider based in London, UK.
Vaccine Contract Manufacturing Market Report 2016-2026: Leading Countries, Technologies and Companies examines the current and future trends in the vaccine contract manufacturing market. Vaccines are a healthcare success, with widespread immunisation eradicating some of the world’s most deadly diseases. The development of new vaccines has historically been limited to a number of large companies due to the high costs involved. However, a growing number of virtual companies and the international demand for new therapeutic vaccines especially, growth in the vaccine contract manufacturing market is accelerating. Another key aspect of the market is the rise of emerging markets as not only a destination for vaccines, but as high quality manufacturing centres for them. While visiongain does not believe this will completely reshape the market, its effects cannot be discounted.
In this report, visiongain examines in detail a number of key national markets (US, Germany, UK, France, Spain, Italy, Japan, China, Russia, Brazil and India), as well as looking at the overall vaccine contract manufacturing market and the key players within it. To give scale to the contract manufacturing business, a global vaccines market forecast is also included. Using visiongain’s experience and market knowledge, as well as a wide variety of sources, forecasts have been built for both national and overall markets, accompanied by text giving a thorough explanation of events thought to shape the market currently and in the future.
Visiongain’s report provides revenue forecasts to 2026 for the vaccine contract manufacturing market and its leading national markets. The report discusses selected leading companies which hold significant shares of the market. These companies include Baxter BioPharma Solutions, Boehringer Ingelheim, Catalent, Charles River Laboratories, IDT Biologika, Lonza, Meridian Life Science, Sigma Aldrich Fine Chemicals (Merck) and Synco Bio Partners.
Vaccine Contract Manufacturing Market Report 2016-2026: Leading Countries, Technologies and Companies adds to visiongain’s range of analytical reports on industries and markets in healthcare.
For an executive summary please contact:
Email: Sara Peerun on firstname.lastname@example.org
Tel: +44 (0) 20 7336 6100
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high quality, original analyses to inform their strategic decisions.
In recent years, the IVD market has experienced increased consolidation among industry participants, with significant merger and acquisition (M&A) activity, especially among larger companies as they diversify and manoeuvre for stronger positions.
14 May 2019
Expected increases in the level of healthcare coverage will allow greater proportion of the population to be able to afford medical care, which is still mostly paid for out-of-pocket by patients, as a greater amount of people have health insurance to cover their medical expenses.
09 May 2019
The major drivers supporting the growth of the mRNA Vaccines and Therapeutics Market are rising adoption of personalized medicine for effective treatment, advantages offered by mRNA-based products, and rising funding by pharmaceutical companies and government organizations.
07 May 2019
The cancer treating drugs market will continue to grow over the next ten years.